Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. markets closed
Hepion Pharmaceuticals, Inc. (HEPA)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
2,818 reactions on $HEPA conversation
Sign in to post a message.
Go long on **CALA** into Q4 and add dips , this stock will move.... consolidated for 6 months and huge catalysts ahead and good Institutions loading
-CB-280- Cystic fibrosis - Phase 1b interim data- 4Q 2021
-Telaglenastat (CB-839) - KEAPSAKE Non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP - Phase 2 interim data due 4Q 2021.
-Mark Lampert’s Biotechnology Value Fund L P has 10.10% stake here ; interesting he wanted 10%+ ownership to be a Major Shareholder before data
BVF disclosed ownership of 7,452,331 shares in July an increase of 70% from their February 2021 filing
BVF was the main institution behind the $FPRX turnaround last year which went from $4s ~> $38 in a $1.9B Buyout by Amgen after a bidding war
$PGEN $JNCE $CASI $HEPA $AGTC
HEPA stock basically selling for cash on the balance sheet despite good p2 results? Shareholders vtoing against mgt? Stock looks super cheap but what part of the story am I missing?
Looks like shareholders voted against increasing number of shares from 120k to 240k, as well as management incentives and pay. Maybe this will be a wake-up call.
Nice presentation from Hobbs
I'm betting very heavily (commons and calls) that we see double digits before the year is out
Vote NO and HOLD
New PR for Hepa
Interview with Dr. Foster in May of this year.
Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster
Hepa CEO youtube video
Dr. Robert Foster Profile - Aurinia Pharmaceuticals/Hepion Pharmaceuticals
Floki. Contravir Pharmaceuticals worked on FV-100 to treat herpes Zoster and post herpetic neuralia and CMX157 to treat Hepatitis B. In 2016 company acquired Ciclofilin from Dr. Foster which worked with Ciclofilin inhibitors to treat liver diseases. In October 2018 Dr. Foster became CEO and in July 2019 the name changed to Hepion. For past three years HEPA has hired great people and their Phase 2a trial went very well in fact showed better results for such a short time compared to other company trials. The market for NASH is big $30 to $50 billion just in the U.S. alone. Phase 2b which whill start soon has a larger pool of patients and will focus on fibrosis biomarkers. In Phase 2b this company will use AI POWR to identify which patients will benefit from their drug. I believe the results will be good so we must wait and see and when it happens within next 18 months the stock will be much higher.
oh no ......good news..... down it goes
I think this week it is going up to 2,00
lots of insider buys in past year
How much do you expect stock prices to rise on Monday?
SA Bullish article is out:
"The next two catalysts are very close: Publication of the complete results of the Phase IIa trial (expected this September), and the start of the Phase IIb trial for next Q4."
Easy $5 soon.. not many know
I think the problem here is Dilution still from the last offering and on top of that they want to add 200mil more shares. Whats This CFO Doing???
⏳📈💰 I.S.T. NEWS ALERT
👉 $HEPA Hepion Pharmaceuticals, Inc. is scheduled to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial of CRV431 before the market opens Monday, Sept. 13,
Here’s How Much You Need To Earn To Be ‘Rich’ in 23 Major Countries Around the World
Social Security checks to rise 5.9% in 2022
Yahoo Finance Video
Wendy's new fry guarantee: hot & crispy, or exchange them 'no questions asked'
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research